C-C chemokine receptor type 4 (CCR4) and CD25 are encouraging targets for the treatment of CTCL and are individually targeted by mogamulizumab and denileukin diftitox, respectively. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.